Abstract
Chemotherapy is the primary treatment for childhood and adult acute lymphoblastic leukemia. The disease-free survival for children is 50% (1) and for adults approximately 40% (2). However, for patients who relapse while receiving drugs, or shortly after the elective cessation of chemotherapy, subsequent treatment has been unsatisfactory (3, 4). Although second complete remissions can usually be attained, the median duration of such remissions has usually been less than six months (3, 4).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Inati A, Sallan SE, Cassady JR et al. 1983. Efficacy and morbidity of central nervous system “prophylaxis” in childhood acute lymphoblastic leukemia: Eight years’ experience with cranial irradiation and intrathecal methotrexate. Blood 61, 297–303.
Schauer P, Arlin ZA, Mertelsmann R et al. 1983. Treatment of acute lymphoblastic leukemia in adults: Results of the L10 and L10M protocols. J Clin Oncol 1, 462–470.
Poplack DG, Reaman GH, Wesley R. 1981. Treatment of acute lymphoblastic leukemia in relapse: Efficacy of a four-drug reinduction regimen. Can Treat Rep 65, 93–96.
Sallan SE, Hitchcock-Bryan S. 1981. Relapse in childhood acute lymphoblastic leukemia after elective cessation of initial treatment: Failure of subsequent treatment. Med Ped Oncol 9, 455–462.
Thomas ED. 1983. Bone marrow transplantation: A lifesaving applied art. J Amer Med Assn 249, 2528–2536.
Dinsmore R, Kirkpatrick D, Flomenberg N et al. 1983. Allogeneic bone marrow transplantation for patients with acute lymphoblastic leukemia. Blood 62, 381–388.
Johnson FL, Thomas ED, Clark BS et al. 1981. A comparison of bone marrow transplantation with chemotherapy for childre with acute lymphoblastic leukemia in second or subsequent remission. N Engl J Med 305, 846–851.
Ritz J, Sallan SE, Bast RC et al. 1982. Autologous bone marrow transplantation in CALLA positive acute lymphoblastic leukaemia after in vitro treatment with J5 monoclonal antibody and complement. Lancet 2, 60–62.
Bast RC, Ritz J, Lipton JM et al. 1983. Elimination of leukemic cells from the human bone marrow using monoclonal antibody and complement. Cancer Res 43, 1389–1394.
Ritz J, Pesando JM, Notis-McConarty J et al. 1980. A monoclonal antibody to human acute lymphoblastic leukaemic antigen. Nature 283, 583–585.
Herchend T, Nadler LM, Pesando JM, Reinherz EL, Schlossman SF, Ritz J. 1981. Expression of a 26, 000 dalton glycoprotein on activated human T-cells. Cell Immunol 64, 192.
Bast RC Jr, DeFabritiis P, Maver C et al. 1983. Elimination of malignant clonogenic cells from human bone marrow using multiple monoclonal antibodies and complement (C’). Amer Assn Can Res 24, 223.
Rivera G, George SL, Bowman WP et al. 1983. Second centra. nervous system prophylaxis in children with acute lymphoblas tic leukemia who relapse after elective cessation of therapy J Clin Oncol 1, 471–476.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1984 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Sallan, S.E., Bast, R.C., Lipton, J.M., Ritz, J. (1984). Autologous Bone Marrow Transplantation in Calla Positive Acute Lymphoblastic Leukemia. In: Löwenberg, B., Hagenbeek, A. (eds) Minimal Residual Disease in Acute Leukemia. Developments in Oncology, vol 19. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-5670-4_19
Download citation
DOI: https://doi.org/10.1007/978-94-009-5670-4_19
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-9002-5
Online ISBN: 978-94-009-5670-4
eBook Packages: Springer Book Archive